Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Eli Lilly (LLY) Hits High After Diabetes Drug Approval
03:24pm, Tuesday, 21'st May 2024
Eli Lilly (LLY) is higher after Chinese regulators approve diabetes drug in China. Diane King Hall discusses this as Eli Lilly's Phase 3 study of Crohn's disease treatment achieves “meaningful impro
Eli Lilly Rises As Study Shows Omvoh Successful in Treating Crohn's Disease
02:31pm, Tuesday, 21'st May 2024
Shares of Eli Lilly (LLY) were on track to close at an all-time high Tuesday as a study showed the pharmaceutical giant's current drug for ulcerative colitis also was successful in treating Crohn's di
Healthy Returns: Eli Lilly, Novo Nordisk are competing to develop more convenient weekly insulins
01:47pm, Tuesday, 21'st May 2024
The rivalry between Eli Lilly and Novo Nordisk extends beyond weight loss and diabetes drugs. Meanwhile, Uber has announced new features for caregivers.
Why Eli Lilly Stock Is Breaking Out
12:05pm, Tuesday, 21'st May 2024
Eli Lilly stock breaks out of a double-bottom base after the pharmaceutical company releases positive data about its Crohn's Disease treatment. New to trading?
Eli Lilly's stock on pace for record close as Crohn's disease trial hits the mark
11:56am, Tuesday, 21'st May 2024
Eli Lilly & Co. LLY shares were on pace for a record closing high Tuesday after the drugmaker released data from a late-stage Crohn's disease trial and struck a deal to develop new cancer-targeting me
If You'd Invested $10,000 in Eli Lilly Stock 5 Years Ago, Here's How Much You'd Have Today
10:41am, Tuesday, 21'st May 2024
Eli Lilly's weight loss drugs are driving growth at the pharma company, generating billions of dollars in revenue. This could continue, considering the strong demand for the products.
Alloy Therapeutics Announces Platform License Agreement with Lilly
08:00am, Tuesday, 21'st May 2024
BOSTON--(BUSINESS WIRE)--Alloy Therapeutics, a biotechnology ecosystem company dedicated to democratizing access to biologics drug discovery platforms and services, announced today a licensing agreeme
Nearly one-half of patients on mirikizumab achieved endoscopic response at 52 weeks; most of these patients were also in clinical remission INDIANAPOLIS, May 21, 2024 /PRNewswire/ -- In Eli Lilly and
3 S&P 500 Stocks to Buy in May Before They Rocket Higher
07:20am, Tuesday, 21'st May 2024
The market is full of prominent stocks, but certain S&P 500 stocks rarely disappoint. I'm talking about the mega-cap giants of industry.
Aktis to collaborate with Eli Lilly on cancer therapies
07:14am, Tuesday, 21'st May 2024
Aktis Oncology said on Tuesday it will collaborate with Eli Lilly to develop cancer therapies, making it eligible for milestone payments of up to $1.1 billion and royalties on sales.
Eli Lilly's (LLY) diabetes injection Mufenda gets approval in China
04:48am, Tuesday, 21'st May 2024
Eli Lilly and Company announced on Tuesday that the National Medical Products Administration (NMPA) in China has approved the distribution of its injection Mufenda. This injection is designed to treat
Eli Lilly's diabetes drug tirzepatide gets approval in China
03:50am, Tuesday, 21'st May 2024
Eli Lilly said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting up intensifying competition with its Danish rival Novo Nordisk in the key Asian market.
Here's How Much $100 Invested In Eli Lilly and Co 5 Years Ago Would Be Worth Today
01:30pm, Monday, 20'th May 2024
Eli Lilly and Co LLY has outperformed the market over the past 5 years by 32.88% on an annualized basis producing an average annual return of 46.32%. Currently, Eli Lilly and Co has a market capitaliz
Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?
06:15am, Sunday, 19'th May 2024
Eli Lilly is generating billions of dollars thanks to its weight loss drugs -- and demand is outpacing supply. Rivals are hoping to carve out share in this high-growth market; Amgen was the latest to
Pharma Stocks Outlook: Where Are 2024's Top Performers Headed Next?
03:02pm, Friday, 17'th May 2024
The three top performing stocks discussed below have appreciated in value by an average of 129.7% in 2024. Such torrid growth logically raises the question of what is possible moving forward.
